DIRS.INFO The most relevant business & tech news

Stabilization of Humira sales after the initial erosion, coupled with strong growth of its newer drugs Skyrizi and Rinvoq for autoimmune disorders, could provide a floor to its earnings in 2024. "Now it's a question of what will the volume erosion look like?" In the fourth quarter, Humira sales dropped 26.5% to $573 million in international markets such as Europe, where it already faces competition from multiple less expensive versions. Overall, Humira sales rose 4.6% to $5.58 billion, in line with estimates, lifted by growth in the U.S. market. Excluding items, AbbVie earned $3.60 per share in the fourth quarter, beating analysts' average estimates by 4 cents.

☆ Drug companies favor biotech meds over pills, citing new U.S. law
▼ + stars: | 2023-01-13 | by ( Deena Beasley | ) www.reuters.com time to read: +5 min

The pharmaceutical industry, whose members gathered in the thousands this week in San Francisco for the annual JP Morgan Healthcare conference, opposed the legislation and has begun implementing strategies to mitigate its impact. "In 10 years, we'll have far fewer small molecules being developed than we do today." He questioned the benefit of "rules that really just disincentivize investment in what ends up being convenient drugs, drugs for tough conditions like cancer and drugs that get really cheap when they go generic." Most medicines on the market today are small molecules, which can be taken by mouth, absorbed into the bloodstream and easily penetrate cell membranes. He noted it is not unusual for pharmaceutical companies to choose not to pursue a drug they once thought promising.

☆ This dividend stock fund is beating the market. Here's its strategy and positions
▼ + stars: | 2023-01-10 | by ( Michelle Fox | ) www.cnbc.com time to read: +6 min

The firm's Integrity Dividend Harvest Fund ended 2022 down just 1.45%, while the broader market saw its worst year since 2008. So far in 2023, Integrity Dividend has gained more than 5%, while the S & P is up only a little more than 1%. IDHIX 1Y mountain Integrity Dividend Harvest I outperformed the S & P 500 in 2022. The stock, which gained more than 19% last year, has a 3.65% dividend yield. "They're pointing to 6% to 7% long-term annual earnings growth, along with dividends growing in lockstep to their earnings," Radke said.

☆ Here's what health insurance providers are doing to lower the cost of prescription drugs
▼ + stars: | 2022-12-09 | by ( Sponsor Post | Created Insider Studios With Unitedhealthcare | ) www.businessinsider.com time to read: +6 min

Americans pay up to three times more for prescription drugs than people in other countries. In the US, people pay up to three times more for prescription drugs than people in other countries, and one in four Americans who take prescription drugs have trouble affording their medications. Because of the high cost of the drug, many diabetes patients cannot afford to pay for the treatment they need. Fast Facts: In the US, people pay 3X more for prescription drugs than people in other countries. The company is eliminating out-of-pocket costs for insulin and four other commonly used prescription drugs: epinephrine, glucagon, naloxone, and albuterol.

☆ What to watch for as J&J gets ready to split into two separate companies next year
▼ + stars: | 2022-12-06 | by ( Paulina Likos | ) www.cnbc.com time to read: +11 min

During Monday's "Morning Meeting" for members, Jim Cramer said that J & J has the "best balance sheet in America." According to projections from J & J and rival Medtronic (MDT), the robotics market captures a low 2% to 3% of global procedures. In an economic slowdown, J & J is a solid name to own that can outperform the broader market. We also like that J & J has consistently raised its dividend. We rate J & J a 1 for the Club , meaning we would buy the stock at current levels given it aligns with our strategy.

Organizations: & $

☆ Merck could keep its patent edge by shifting Keytruda cancer drug to a simple shot
▼ + stars: | 2022-12-02 | by ( Michael Erman | ) www.reuters.com time to read: +7 min

If successful, Merck could begin marketing the new formulation within a few years, a top Merck executive told Reuters. "The clock for that patent would start ticking from the time we would get that patent approved." Drug patents have a guaranteed term of exclusivity for 20 years after receiving a patent under U.S. law, but sometimes the companies are able to add additional patents that extend their exclusivity. Merck's patents on the subcutaneous version of Keytruda could protect that formulation until at least 2040, according to Tahir Amin, co-founder of drug patents watchdog group Initiative for Medicines, Access & Knowledge (I-MAK). Northwell's Mulloy said moving patients to subcutaneous versions of drugs also opens up spots in infusion centers for additional patients.

Stelara accounted for $9.1 billion of J&J's $52 billion in global drug sales last year. The drug is also approved to treat Crohn's disease, the skin condition psoriasis and a related form of arthritis. However, J&J alleges that Amgen failed to follow the legal process required by that law for the companies to litigate any patent disputes. If Amgen launches its drug, J&J said it would infringe J&J's patent on the drug's active ingredient and on its use for treating ulcerative colitis. J&J said in a statement that Janssen is "confident in its intellectual property and has filed suit to protect its rights."

Organizations: & &'

One of the biggest makers of generic drugs, Israeli-based Teva said it aims eventually to secure a 10% global market share of biosimilars. A division of Novartis (NOVN.S), Sandoz is currently the second biggest player after Pfizer Inc (PFE.N) in the biosimilar market by gross sales globally, per IQVIA data, cited by Sandoz. Sandoz launched eight biosimilar drugs between 2017 and 2021, including a version of Bristol-Myers’ multiple myeloma drug Revlimid. The analysis projected the value of the global biosimilar market could more than triple to an estimated $74 billion by 2030. Sandoz and Teva are both working on biosimilars for Humira.

☆ JPMorgan downgrades Teva as generic medication business struggles
▼ + stars: | 2022-11-14 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Teva Pharmaceutical is hard to like as it continues to be weighed down by underperformance in some business areas, JPMorgan says. The new price target implies upside of just 5.5% from Friday's close. Schott noted the company has been able to continue paying down debt as a positive, but said it would need to continue allocating cash pay towards this. The stock's performance could be impacted by improvements in generics, a favorable opioid settlement or if the company is able to stave off competition on its migraine medication Ajovy. Teva shed 2.3% in the premarket and is up 18.4% compared with the start of the year.

☆ UBS downgrades Teva to sell as CEO exit, ongoing litigation cloud the pharma stock's outlook
▼ + stars: | 2022-11-04 | by ( Carmen Reinicke | ) www.cnbc.com time to read: +2 min

It's time to sell Teva stock as it's facing a period of significant downside amid a phase of uncertainty, according to UBS. However, Teva's development partner Alvotech recently received an observation letter from the FDA that puts the launch date at risk, Verma wrote. Without a drug similar to Humira, there's significant downside to earnings for Teva. Price fixing risk Teva is also facing headline risk from litigation concerning price fixing, according to the note. "The DOJ price fixing case outcome may involve potential debarment from conducting business in the government channel (worse case) and/or cash settlement in the $525m-$595m range," wrote Verma.

☆ 3 of our stocks are in the news — here's our take on what's happening
▼ + stars: | 2022-09-21 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +10 min

Scharf, who took over the troubled lender in October 2019, said in his congressional testimony Wednesday that Wells Fargo has "approximately $1.9 trillion in assets." The Club take: Our investment thesis in Wells Fargo largely rests on a two-pronged approach to boost earnings. As rates rise, Wells Fargo can make more money on the spread between what it pays customers for deposits and what it charges for loans. Still, intensifying recession fears have ultimately been a drag on Wells Fargo shares this year. Investors must be realists, though, and our stake in Wells Fargo never assumed it would be a quick fix.

☆ Deputat PAS: Din cauza unor interese financiare, unii diabetici dependenți de insulină sunt nevoiți să-și administreze insulină cu termenul de valabilitate expirat
▼ + stars: | 2021-05-21 | by ( Mudrii Elena | ) www.zdg.md time to read: +3 min

Deputatul PAS, Dan Perciun susține că diabeticii dependenți de insulină suferă din cauza gestionării proaste a procesului de achiziții publice. Ministerul Sănătății, Muncii și Protecției Sociale nu a venit, deocamdată, cu o reacție la cele declarate de parlamentar. „Astăzi am fost la policlinica Buiucani după insulină și mi-au spus că NovoRapid nu mai este și nici nu va mai fi. Doamnei, farmacista îi propunea să ia insulină și să și-o administreze inclusiv după expirarea termenului de valabilitate”, a mai declarat deputatul. În martie 2021 termenul de valabilitate pentru această insulină a expirat.

Persons: Dan Perciun Organizations: Ministerul Sănătății, Muncii, Sociale, Sănătății, Protecției Sociale Locations: ucraineană

Search resuls for: "biosimilar"

12 mentions found